Subscribe to RSS
DOI: 10.1055/s-0031-1297934
How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective
Publication History
received 23 July 2011
revised 06 September 2011
accepted 16 October 2011
Publication Date:
15 December 2011 (online)
Abstract
Introduction:
While patients with schizophrenia are often treated with psychotropic polypharmacy, how and when polypharmacy begins is not well documented.
Methods:
A systematic chart review of 300 patients, 100 of whom were psychotropic-free prior to their first visit, was conducted to examine 2-year longitudinal prescription patterns of concomitant psychotropics, in addition to a primary antipsychotic.
Results:
Overall polypharmacy occurred in 79% patients, with 2-year rates of the use of hypnotics, benzodiazepine derivative anxiolytics, anticholinergic drugs, antidepressants, and mood stabilizers were 56.7, 49.7, 38.3, 21.3, and 14.0%, respectively. Once polypharmacy had started, it was continued until their final visit in >70% of the patients. In a subgroup of 100 psychotropic-free patients, mood stabilizers, antidepressants, anticholinergic antiparkinsonian drugs, anxiolytics, and hypnotics were initiated after 2.3, 2.3, 2.1, 1.6, and 1.5 antipsychotics had been prescribed, respectively (mean duration before the introduction of a concomitant drug in days: 17.7, 121.6, 86.4, 32.1, and, 57.7, respectively).
Conclusion:
Routine practice deviates significantly from algorithms – with polypharmacy often being initiated early, often a without trial of other options, and once started commonly stays.